Angioedema; Urticaria - Primary; rash nonstop,body itchy rash; This spontaneous case was reported by a consumer and describes the occurrence of ANGIOEDEMA (Angioedema) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Allergy (I have the same allergy reactions too).    On 09-Jun-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ANGIOEDEMA (Angioedema) (seriousness criterion medically significant), URTICARIA (Urticaria - Primary) and RASH PRURITIC (rash nonstop,body itchy rash). The patient was treated with FEXOFENADINE HCL for Itching and Rash, at a dose of Morning and HYDROXYZINE for Itching and Rash, at a dose of night. At the time of the report, ANGIOEDEMA (Angioedema), URTICARIA (Urticaria - Primary) and RASH PRURITIC (rash nonstop,body itchy rash) had not resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Patient had the same allergy reactions too. Patient took first dose on 9 June 2021, Moderna Vaccine. Second shot will be on this coming 21st July. Patient visited to the Hospital before after 1 week first dose since body rash and itchy nonstop. But doctor was mention that its cause by vaccine effects. After visit patient got diagnosis Urticaria - Primary and Angioedema. Until now this body itchy rash coming but a sometime and patient still taking medicine which is Fexofenadine HC1 - Morning & hydOXYzie - Night. patient was just thinking how long this itchy will going and is it possible it will never stop even after second vaccines? patient just don't like to consume medicine for the rest of life huhu..  No concomitant product was provided.  Company Comment: This case concerns a patient of an unknown age and gender, with relevant medical history of Allergy, who experienced the unexpected serious (medically significant) event of Angioedema, and the unexpected events of Urticaria and Rash pruritic. The events occurred on an unknown date after receiving the first dose of mRNA-1273 Vaccine. At the time of the report the outcome of the events was not resolved. The rechallenge is not applicable as the events occurred after the first dose and no information about second dose is available. The patient's medical history of Allergy remain as a confounder for the occurrence of the events. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.; Sender's Comments: This case concerns a patient of an unknown age and gender, with relevant medical history of Allergy, who experienced the unexpected serious (medically significant) event of Angioedema, and the unexpected events of Urticaria and Rash pruritic. The events occurred on an unknown date after receiving the first dose of mRNA-1273 Vaccine. At the time of the report the outcome of the events was not resolved. The rechallenge is not applicable as the events occurred after the first dose and no information about second dose is available. The patient's medical history of Allergy remain as a confounder for the occurrence of the events. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.